Ligand Pharmaceuticals (NASDAQ: LGND)
Key Data Points
Ligand Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Ligand Pharmaceuticals Company Info
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
News & Analysis
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
3 Signs the Ligand Short Squeeze Is Over
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
Forget Gamestop! This Highly Shorted Stock Is A Strong Buy Now
The unusual biotech could be a bitter pill for short sellers to swallow.
Short-Sellers Have These 3 ETFs in Their Sights
Should investors watch for a squeeze?
Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir
The company posted strong revenue and earnings growth in Q2 and upped its full-year outlook.
3 Top Biotech Stocks to Buy in August
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
5 Top Biotech Stocks to Buy in 2019
Looking for potential winning biotech stocks? These five check off all the boxes for investors.
Here's Why Ligand Pharmaceuticals Is Having a Bad Day
Investors are not impressed with the company's plan to finance an acquisition spree.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.